Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ATNM Actinium Pharmaceuticals, Inc
$1.17 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ATNM stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 36.2M
Enterprise value -14812931
Trailing PE -0.91338582677165
Forward PE -1.5189874
PEG Ratio 0.016092988376453
Enterprise to EBITDA 0.399
Enterprise to revenue -164.588
Price to book MRQ 2.7149322
Price to sales TTM 415.94525

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 90000
EBITDA -37123000
Diluted EPS TTM -1.11
Total Cash (MRQ) 53.4M
Current ratio (MRQ) 7.955
Operating Cash Flow (TTM) -25042000

ATNM trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ATNM News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.